The proportions of patients who reported at least some problems with “anxiety/depression” were 46.9% at baseline and 35.4% at 24 months in the exenatide BID cohort; respective values were 47.6% and 35.9% in the insulin cohort. Here, INS is linked to depressive symptom measurement.